These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 20003696

  • 1. Experience establishing tuberculosis laboratory capacity in a developing country setting.
    Paramasivan CN, Lee E, Kao K, Mareka M, Kubendiran G, Kumar TA, Keshavjee S, Satti H, Alabi G, Raviglione M, Roscigno G.
    Int J Tuberc Lung Dis; 2010 Jan; 14(1):59-64. PubMed ID: 20003696
    [Abstract] [Full Text] [Related]

  • 2. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda.
    Ssengooba W, Gelderbloem SJ, Mboowa G, Wajja A, Namaganda C, Musoke P, Mayanja-Kizza H, Joloba ML.
    Health Res Policy Syst; 2015 Jan 15; 13():4. PubMed ID: 25589057
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Human resource capacity building on TB laboratory work for TB control program--through the experience of international TB laboratory training course for TB control at the Research Institute of Tuberculosis, JATA, Japan].
    Fujiki A, Kato S.
    Kekkaku; 2008 Jun 15; 83(6):475-9. PubMed ID: 18634453
    [Abstract] [Full Text] [Related]

  • 6. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
    Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, Paramasivan CN, Narayanan PR, Sahu S, Parmar M, Chadha S, Dewan P, Chauhan LS.
    Int J Tuberc Lung Dis; 2009 Sep 15; 13(9):1154-60. PubMed ID: 19723407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S, Mokaddas E.
    Respir Med; 2009 Dec 15; 103(12):1777-90. PubMed ID: 19660927
    [Abstract] [Full Text] [Related]

  • 9. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
    Yoshiyama T, Yanai H, Rhiengtong D, Palittapongarnpim P, Nampaisan O, Supawitkul S, Uthaivorawit W, Mori T.
    Int J Tuberc Lung Dis; 2004 Jan 15; 8(1):31-8. PubMed ID: 14974743
    [Abstract] [Full Text] [Related]

  • 10. Certification of TB culture and drug susceptibility testing laboratories through the Revised National Tuberculosis Control Programme (RNTCP).
    Sachdeva KS, Nagaraja SB, Kumar A, Kumar P, Ramachandran R.
    J Indian Med Assoc; 2012 Jul 15; 110(7):488-9. PubMed ID: 23520677
    [Abstract] [Full Text] [Related]

  • 11. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy. The Italian Drug-Resistant Tuberculosis Study Group.
    Angarano G, Carbonara S, Costa D, Gori A.
    Int J Tuberc Lung Dis; 1998 Apr 15; 2(4):303-11. PubMed ID: 9559401
    [Abstract] [Full Text] [Related]

  • 12. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB.
    Ejigu GS, Woldeamanuel Y, Shah NS, Gebyehu M, Selassie A, Lemma E.
    Int J Tuberc Lung Dis; 2008 Mar 15; 12(3):332-7. PubMed ID: 18284841
    [Abstract] [Full Text] [Related]

  • 13. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A, Gowda DK, Frieden TR.
    Bull World Health Organ; 2002 Mar 15; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [Abstract] [Full Text] [Related]

  • 14. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, Werner B, Sloutsky A, Timperi R, Wilson ME, Pagano M, Farmer PE.
    Int J Tuberc Lung Dis; 2000 Feb 15; 4(2):108-14. PubMed ID: 10694087
    [Abstract] [Full Text] [Related]

  • 15. New diagnostics for latent and active tuberculosis: state of the art and future prospects.
    Pai M, O'Brien R.
    Semin Respir Crit Care Med; 2008 Oct 15; 29(5):560-8. PubMed ID: 18810689
    [Abstract] [Full Text] [Related]

  • 16. The Global TB Drug Facility: innovative global procurement.
    Kumaresan J, Smith I, Arnold V, Evans P.
    Int J Tuberc Lung Dis; 2004 Jan 15; 8(1):130-8. PubMed ID: 14974756
    [Abstract] [Full Text] [Related]

  • 17. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA.
    Int J Infect Dis; 2009 Sep 15; 13(5):e236-40. PubMed ID: 19285897
    [Abstract] [Full Text] [Related]

  • 18. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
    Rajasekaran S, Chandrasekar C, Mahilmaran A, Kanakaraj K, Karthikeyan DS, Suriakumar J.
    J Indian Med Assoc; 2009 May 15; 107(5):281-2, 284-6. PubMed ID: 19886382
    [Abstract] [Full Text] [Related]

  • 19. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance.
    Pai M, Kalantri S, Dheda K.
    Expert Rev Mol Diagn; 2006 May 15; 6(3):423-32. PubMed ID: 16706744
    [Abstract] [Full Text] [Related]

  • 20. High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting.
    Satti H, McLaughlin MM, Seung KJ, Becerra MC, Keshavjee S.
    Int J Tuberc Lung Dis; 2013 Jan 15; 17(1):100-6. PubMed ID: 23232009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.